Bessemer Group Inc. Grows Stock Holdings in Globus Medical, Inc. $GMED

Bessemer Group Inc. raised its position in shares of Globus Medical, Inc. (NYSE:GMED) by 1,078.9% during the fourth quarter, HoldingsChannel reports. The firm owned 357,886 shares of the medical device company’s stock after purchasing an additional 327,529 shares during the period. Bessemer Group Inc.’s holdings in Globus Medical were worth $31,247,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in GMED. SBI Securities Co. Ltd. boosted its holdings in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Globus Medical by 2.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock worth $375,000 after buying an additional 170 shares during the period. Parallel Advisors LLC boosted its holdings in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares during the period. Finally, Probity Advisors Inc. boosted its holdings in shares of Globus Medical by 5.5% during the 3rd quarter. Probity Advisors Inc. now owns 3,792 shares of the medical device company’s stock valued at $217,000 after purchasing an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Down 0.9%

GMED opened at $76.52 on Friday. The firm has a 50-day simple moving average of $87.78 and a two-hundred day simple moving average of $87.08. The company has a market capitalization of $10.39 billion, a PE ratio of 17.79, a price-to-earnings-growth ratio of 1.58 and a beta of 1.00. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business’s revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GMED has been the subject of several research reports. Wells Fargo & Company dropped their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Royal Bank Of Canada increased their price objective on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. TD Cowen raised shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Needham & Company LLC increased their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Insider Activity

In other news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 18.38% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.